Variability in plasma rifampicin concentrations and role of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis
BACKGROUND: Rifampicin, a key drug against tuberculosis (TB), displays wide between-patient pharmacokinetics variability and concentration-dependent antimicrobial effect. We investigated variability in plasma rifampicin concentrations and the role of SLCO1B1, ABCB1, arylacetamide deacetylase (AADAC) and carboxylesterase 2 (CES-2) genotypes in Ethiopian patients with TB.
METHODS: We enrolled adult patients with newly diagnosed TB (n = 119) who had received 2 weeks of rifampicin-based anti-TB therapy. Venous blood samples were obtained at three time points post-dose. Genotypes for SLCO1B1 (c.388A > G, c.521T > C), ABCB1 (c.3435C > T, c.4036A > G), AADACc.841G > A and CES-2 (c.269-965A > G) were determined. Rifampicin plasma concentration was quantified using LC-MS/MS. Predictors of rifampicin Cmax and AUC0-7 h were analysed.
RESULTS: The median rifampicin Cmax and AUC0-7 were 6.76 µg/mL (IQR 5.37-8.48) and 17.05 µg·h/mL (IQR 13.87-22.26), respectively. Only 30.3% of patients achieved the therapeutic efficacy threshold (Cmax>8 µg/mL). The allele frequency for SLCO1B1*1B (c.388A > G), SLCO1B1*5 (c.521T > C), ABCB1 c.3435C > T, ABCB1c.4036A > G, AADAC c.841G > A and CES-2 c.269-965A > G were 2.2%, 20.2%, 24.4%, 14.6%, 86.1% and 30.6%, respectively. Sex, rifampicin dose and ABCB1c.4036A > G, genotypes were significant predictors of rifampicin Cmax and AUC0-7. AADACc.841G > A genotypes were significant predictors of rifampicin Cmax. There was no significant influence of SLCO1B1 (c.388A > G, c.521T > C), ABCB1c.3435C > T and CES-2 c.269-965A > G on rifampicin plasma exposure variability.
CONCLUSIONS: Subtherapeutic rifampicin plasma concentrations occurred in two-thirds of Ethiopian TB patients. Rifampicin exposure varied with sex, dose and genotypes. AADACc.841G/G and ABCB1c.4036A/A genotypes and male patients are at higher risk of lower rifampicin plasma exposure. The impact on TB treatment outcomes and whether high-dose rifampicin is required to improve therapeutic efficacy requires further investigation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
---|---|
Enthalten in: |
Infectious diseases (London, England) - 56(2024), 4 vom: 22. März, Seite 308-319 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sileshi, Tesemma [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/23744235.2024.2309348 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368044416 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368044416 | ||
003 | DE-627 | ||
005 | 20240318234218.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240206s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/23744235.2024.2309348 |2 doi | |
028 | 5 | 2 | |a pubmed24n1334.xml |
035 | |a (DE-627)NLM368044416 | ||
035 | |a (NLM)38315168 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sileshi, Tesemma |e verfasserin |4 aut | |
245 | 1 | 0 | |a Variability in plasma rifampicin concentrations and role of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.03.2024 | ||
500 | |a Date Revised 18.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Rifampicin, a key drug against tuberculosis (TB), displays wide between-patient pharmacokinetics variability and concentration-dependent antimicrobial effect. We investigated variability in plasma rifampicin concentrations and the role of SLCO1B1, ABCB1, arylacetamide deacetylase (AADAC) and carboxylesterase 2 (CES-2) genotypes in Ethiopian patients with TB | ||
520 | |a METHODS: We enrolled adult patients with newly diagnosed TB (n = 119) who had received 2 weeks of rifampicin-based anti-TB therapy. Venous blood samples were obtained at three time points post-dose. Genotypes for SLCO1B1 (c.388A > G, c.521T > C), ABCB1 (c.3435C > T, c.4036A > G), AADACc.841G > A and CES-2 (c.269-965A > G) were determined. Rifampicin plasma concentration was quantified using LC-MS/MS. Predictors of rifampicin Cmax and AUC0-7 h were analysed | ||
520 | |a RESULTS: The median rifampicin Cmax and AUC0-7 were 6.76 µg/mL (IQR 5.37-8.48) and 17.05 µg·h/mL (IQR 13.87-22.26), respectively. Only 30.3% of patients achieved the therapeutic efficacy threshold (Cmax>8 µg/mL). The allele frequency for SLCO1B1*1B (c.388A > G), SLCO1B1*5 (c.521T > C), ABCB1 c.3435C > T, ABCB1c.4036A > G, AADAC c.841G > A and CES-2 c.269-965A > G were 2.2%, 20.2%, 24.4%, 14.6%, 86.1% and 30.6%, respectively. Sex, rifampicin dose and ABCB1c.4036A > G, genotypes were significant predictors of rifampicin Cmax and AUC0-7. AADACc.841G > A genotypes were significant predictors of rifampicin Cmax. There was no significant influence of SLCO1B1 (c.388A > G, c.521T > C), ABCB1c.3435C > T and CES-2 c.269-965A > G on rifampicin plasma exposure variability | ||
520 | |a CONCLUSIONS: Subtherapeutic rifampicin plasma concentrations occurred in two-thirds of Ethiopian TB patients. Rifampicin exposure varied with sex, dose and genotypes. AADACc.841G/G and ABCB1c.4036A/A genotypes and male patients are at higher risk of lower rifampicin plasma exposure. The impact on TB treatment outcomes and whether high-dose rifampicin is required to improve therapeutic efficacy requires further investigation | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a AADAC | |
650 | 4 | |a ABCB1 | |
650 | 4 | |a CES-2 | |
650 | 4 | |a Ethiopia | |
650 | 4 | |a Rifampicin | |
650 | 4 | |a SLCO1B1 | |
650 | 4 | |a genotype | |
650 | 4 | |a pharmacogenetics | |
650 | 4 | |a pharmacokinetics | |
650 | 4 | |a tuberculosis | |
650 | 7 | |a Rifampin |2 NLM | |
650 | 7 | |a VJT6J7R4TR |2 NLM | |
650 | 7 | |a SLCO1B1 protein, human |2 NLM | |
650 | 7 | |a Liver-Specific Organic Anion Transporter 1 |2 NLM | |
650 | 7 | |a ABCB1 protein, human |2 NLM | |
650 | 7 | |a ATP Binding Cassette Transporter, Subfamily B |2 NLM | |
650 | 7 | |a CES2 protein, human |2 NLM | |
650 | 7 | |a EC 3.1.1.1 |2 NLM | |
650 | 7 | |a Carboxylesterase |2 NLM | |
650 | 7 | |a EC 3.1.1.1 |2 NLM | |
700 | 1 | |a Makonnen, Eyasu |e verfasserin |4 aut | |
700 | 1 | |a Telele, Nigus Fikrie |e verfasserin |4 aut | |
700 | 1 | |a Barclay, Victoria |e verfasserin |4 aut | |
700 | 1 | |a Zumla, Alimuddin |e verfasserin |4 aut | |
700 | 1 | |a Aklillu, Eleni |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Infectious diseases (London, England) |d 2015 |g 56(2024), 4 vom: 22. März, Seite 308-319 |w (DE-627)NLM242918921 |x 2374-4243 |7 nnns |
773 | 1 | 8 | |g volume:56 |g year:2024 |g number:4 |g day:22 |g month:03 |g pages:308-319 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/23744235.2024.2309348 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 56 |j 2024 |e 4 |b 22 |c 03 |h 308-319 |